CN115698286A - 外泌体衍生的piwi-相互作用rna及使用其的方法 - Google Patents

外泌体衍生的piwi-相互作用rna及使用其的方法 Download PDF

Info

Publication number
CN115698286A
CN115698286A CN202180040396.0A CN202180040396A CN115698286A CN 115698286 A CN115698286 A CN 115698286A CN 202180040396 A CN202180040396 A CN 202180040396A CN 115698286 A CN115698286 A CN 115698286A
Authority
CN
China
Prior art keywords
pir
derived
pirna
exosome
hsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180040396.0A
Other languages
English (en)
Chinese (zh)
Inventor
爱德华多·马尔万
亚历山德拉·丘洛
艾哈迈德·G·易卜拉欣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of CN115698286A publication Critical patent/CN115698286A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180040396.0A 2020-05-19 2021-05-17 外泌体衍生的piwi-相互作用rna及使用其的方法 Pending CN115698286A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063027191P 2020-05-19 2020-05-19
US63/027,191 2020-05-19
PCT/US2021/070568 WO2021237238A1 (en) 2020-05-19 2021-05-17 Exosome-derived piwi-interacting rna and methods of use thereof

Publications (1)

Publication Number Publication Date
CN115698286A true CN115698286A (zh) 2023-02-03

Family

ID=78707679

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180040396.0A Pending CN115698286A (zh) 2020-05-19 2021-05-17 外泌体衍生的piwi-相互作用rna及使用其的方法

Country Status (6)

Country Link
US (1) US20230203487A1 (de)
EP (1) EP4153743A4 (de)
JP (1) JP2023527766A (de)
CN (1) CN115698286A (de)
AU (1) AU2021275327A1 (de)
WO (1) WO2021237238A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
EP4699658A2 (de) 2017-04-19 2026-02-25 Cedars-Sinai Medical Center Verfahren und zusammensetzungen zur behandlung von skelettmuskeldystrophie
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
US12146137B2 (en) 2018-02-05 2024-11-19 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and Y-RNAS
CN116875682B (zh) * 2023-07-08 2024-06-11 中国人民解放军总医院第二医学中心 用于诊断急性心肌梗死心脏损伤的piRNA标志物、试剂盒及其应用
WO2026035943A1 (en) 2024-08-08 2026-02-12 Cedars-Sinai Medical Center Formulations for oral delivery of nucleic acids
CN120485350B (zh) * 2025-04-12 2026-04-10 中国人民解放军总医院第二医学中心 用于诊断评估脓毒症心肌病的piRNA标志物、试剂盒及其应用
CN120713928A (zh) * 2025-06-30 2025-09-30 山西农业大学 miR-126及携带miR-126的外泌体在促进骨骼肌损伤修复和增殖分化中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015092020A2 (en) * 2013-12-20 2015-06-25 Université de Lausanne Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine
WO2019152549A1 (en) * 2018-02-05 2019-08-08 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and y-rnas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104548136B (zh) * 2015-01-27 2018-02-13 青岛大学 一种piRNA药物组合物及其用途
EP3420086A1 (de) * 2016-02-26 2019-01-02 Yale University Zusammensetzungen und verfahren zur verwendung von pirnas bei krebsdiagnostika und -therapeutika
ES2785682T3 (es) * 2017-07-17 2020-10-07 Univ Masarykova Método de diagnóstico de cáncer colorrectal
WO2019050071A1 (ko) * 2017-09-08 2019-03-14 고려대학교 산학협력단 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015092020A2 (en) * 2013-12-20 2015-06-25 Université de Lausanne Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine
WO2019152549A1 (en) * 2018-02-05 2019-08-08 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and y-rnas

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SERENA VELLA: ""PIWI-interacting RNA (piRNA) signatures in human cardiac progenitor cells Author links open overlay panel"", 《THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY》, 30 July 2016 (2016-07-30), pages 1 - 11 *

Also Published As

Publication number Publication date
JP2023527766A (ja) 2023-06-30
WO2021237238A1 (en) 2021-11-25
AU2021275327A1 (en) 2022-12-08
EP4153743A1 (de) 2023-03-29
EP4153743A4 (de) 2025-09-24
US20230203487A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
CN115698286A (zh) 外泌体衍生的piwi-相互作用rna及使用其的方法
US11708396B2 (en) Signal-sensor polynucleotides for the alteration of cellular phenotypes
US12023371B2 (en) Terminally modified RNA
JP2023119040A (ja) 遺伝子発現をモジュレートするための方法および組成物
US20240158458A1 (en) Mrnas encoding immune modulating polypeptides and uses thereof
EP2914728A1 (de) Verfahren und produkte zur expression von proteinen in zellen
CN101072866A (zh) 通过施用rna改变细胞性质的方法
US20240123034A1 (en) Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
JP2021522865A (ja) 栄養要求性調節可能な細胞を使用する遺伝子療法の方法および組成物
US20240374649A1 (en) Method for Treating Ilk Signaling Pathway Related Diseases Using Exosome Derived from Mesenchymal Stem Cells, and Pharmaceutical Composition
HK40080438A (en) Terminally modified rna
Merour Characterization of Tns3 molecular mechanisms in oligodendrogenesis
CN104208660B (zh) 低分子量碱性成纤维细胞生长因子lmw fgf2的应用
HK40005169A (en) Signal-sensor polynucleotides for the alteration of cellular phenotypes
Carbone et al. Placenta-Derived Stem Cells as a Source for Treatment of Lung and Liver Disease in Cystic Fibrosis
HK1214515B (en) Terminally modified rna

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination